| 1.66 -0.02 (-1.19%) | 10-28 12:08 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 2.39 | 1-year : | 2.79 |
| Resists | First : | 2.04 | Second : | 2.39 |
| Pivot price | 1.77 |
|||
| Supports | First : | 1.54 | Second : | 1.23 |
| MAs | MA(5) : | 1.69 |
MA(20) : | 1.71  |
| MA(100) : | 1.26 |
MA(250) : | 0.8 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 32.2 |
D(3) : | 39.4 |
| RSI | RSI(14): 47.5 |
|||
| 52-week | High : | 3.82 | Low : | 0.22 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ CGTX ] has closed above bottom band by 14.1%. Bollinger Bands are 67.4% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 1.77 - 1.78 | 1.78 - 1.79 |
| Low: | 1.64 - 1.65 | 1.65 - 1.66 |
| Close: | 1.66 - 1.68 | 1.68 - 1.7 |
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Wed, 08 Oct 2025
Cognition Therapeutics (CGTX) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Mon, 15 Sep 2025
Cognition Therapeutics Advances Zervimesine to Phase 3 Trials - TipRanks
Tue, 02 Sep 2025
$30 Million Funding: Cognition Therapeutics Advances Breakthrough Neurodegenerative Drug to Phase 3 - Stock Titan
Wed, 27 Aug 2025
$30M Stock Offering: Cognition Therapeutics Advances Phase 3 Programs for Neurodegenerative Drug - Stock Titan
Wed, 27 Aug 2025
Cognition Therapeutics Announces $30 Million Registered Direct Offering of Common Stock - GlobeNewswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Neutral |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Neutral |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 88 (M) |
| Shares Float | 73 (M) |
| Held by Insiders | 0.7 (%) |
| Held by Institutions | 15.8 (%) |
| Shares Short | 8,440 (K) |
| Shares Short P.Month | 9,000 (K) |
| EPS | -0.67 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.1 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -122.6 % |
| Return on Equity (ttm) | -219.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -0.6 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -31 (M) |
| Levered Free Cash Flow | -32 (M) |
| PE Ratio | -2.53 |
| PEG Ratio | 0 |
| Price to Book value | 15.13 |
| Price to Sales | 0 |
| Price to Cash Flow | -4.78 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|